Sight Sciences Inc., of Menlo Park, Calif., scooped up $30 million in a series E preferred stock financing round that was led by D1 Capital Partners. The funds are earmarked to further advance clinical and operational development and support commercial expansion of the company’s Omni surgical and Tearcare systems.